28 July 2021 - Across four Phase 3 studies, approximately half of patients receiving faricimab could extend treatment time to every four months – the first time this level of durability has been achieved in Phase 3 age-related macular degeneration and diabetic macular oedema studies.

Genentech today announced that the U.S. FDA has accepted the company’s biologics license application, under priority review, for faricimab for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular oedema. 

The FDA has also accepted the company’s submission for diabetic retinopathy.

Read Genentech press release